Literature DB >> 31503550

Molecular determinants of response to high-dose androgen therapy in prostate cancer.

Michael D Nyquist1, Alexandra Corella1, Osama Mohamad2, Ilsa Coleman1, Arja Kaipainen1, Daniel A Kuppers1, Jared M Lucas1, Patrick J Paddison1, Stephen R Plymate3,4, Peter S Nelson1,3, Elahe A Mostaghel1,3,4.   

Abstract

Clinical trials of high-dose androgen (HDA) therapy for prostate cancer (PC) have shown promising efficacy but are limited by lack of criteria to identify likely responders. To elucidate factors that govern the growth-repressive effects of HDAs, we applied an unbiased integrative approach using genetic screens and transcriptional profiling of PC cells with or without demonstrated phenotypic sensitivity to androgen-mediated growth repression. Through this comprehensive analysis, we identified genetic events and related signaling networks that determine the response to both HDA and androgen withdrawal. We applied these findings to develop a gene signature that may serve as an early indicator of treatment response and identify men with tumors that are amenable to HDA therapy.

Entities:  

Keywords:  Cancer; Genetics; Oncology; Prostate cancer; Tumor suppressors

Mesh：

Substances：

Year:  2019        PMID： 31503550      PMCID： PMC6795499          DOI： 10.1172/jci.insight.129715

Source DB:  PubMed          Journal:  JCI Insight        ISSN： 2379-3708


  59 in total

1.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.

Authors:  Changmeng Cai; Housheng Hansen He; Sen Chen; Ilsa Coleman; Hongyun Wang; Zi Fang; Shaoyong Chen; Peter S Nelson; X Shirley Liu; Myles Brown; Steven P Balk
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

Review 2.  The role of GATA2 in lethal prostate cancer aggressiveness.

Authors:  Veronica Rodriguez-Bravo; Marc Carceles-Cordon; Yujin Hoshida; Carlos Cordon-Cardo; Matthew D Galsky; Josep Domingo-Domenech
Journal:  Nat Rev Urol       Date:  2016-11-22       Impact factor: 14.432

3.  Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.

Authors:  John T Isaacs; Jason M D'Antonio; Shuangling Chen; Lizamma Antony; Susan P Dalrymple; Georges H Ndikuyeze; Jun Luo; Samuel R Denmeade
Journal:  Prostate       Date:  2012-03-06       Impact factor: 4.104

4.  Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein.

Authors:  Shuai Gao; Yanfei Gao; Housheng Hansen He; Dong Han; Wanting Han; Amy Avery; Jill A Macoska; Xiaming Liu; Sen Chen; Fen Ma; Shaoyong Chen; Steven P Balk; Changmeng Cai
Journal:  Cell Rep       Date:  2016-10-18       Impact factor: 9.423

5.  Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy.

Authors:  Jehonathan H Pinthus; Inna Bryskin; John Trachtenberg; Jiang-Ping Lu; Gurmit Singh; Eduard Fridman; Brian C Wilson
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

6.  Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Prostate       Date:  2010-10-01       Impact factor: 4.104

7.  Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer.

Authors:  Benjamin A Teply; Sushant Kachhap; Mario A Eisenberger; Samuel R Denmeade
Journal:  Eur Urol       Date:  2016-09-29       Impact factor: 20.096

8.  SOX4 Is Essential for Prostate Tumorigenesis Initiated by PTEN Ablation.

Authors:  Birdal Bilir; Adeboye O Osunkoya; W Guy Wiles; Soma Sannigrahi; Veronique Lefebvre; Daniel Metzger; Demetri D Spyropoulos; W David Martin; Carlos S Moreno
Journal:  Cancer Res       Date:  2015-12-23       Impact factor: 12.701

9.  Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Authors:  Benjamin A Teply; Hao Wang; Brandon Luber; Rana Sullivan; Irina Rifkind; Ashley Bruns; Avery Spitz; Morgan DeCarli; Victoria Sinibaldi; Caroline F Pratz; Changxue Lu; John L Silberstein; Jun Luo; Michael T Schweizer; Charles G Drake; Michael A Carducci; Channing J Paller; Emmanuel S Antonarakis; Mario A Eisenberger; Samuel R Denmeade
Journal:  Lancet Oncol       Date:  2017-12-14       Impact factor: 41.316

10.  Cooperative tumorigenic effects of germline mutations in Rb and p53.

Authors:  B O Williams; L Remington; D M Albert; S Mukai; R T Bronson; T Jacks
Journal:  Nat Genet       Date:  1994-08       Impact factor: 38.330
View more
  4 in total

1.  Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome.

Authors:  Xintao Qiu; Lisha G Brown; Jennifer L Conner; Holly M Nguyen; Nadia Boufaied; Sarah Abou Alaiwi; Ji-Heui Seo; Talal El Zarif; Connor Bell; Edward O'Connor; Brian Hanratty; Mark Pomerantz; Matthew L Freedman; Myles Brown; Michael C Haffner; Peter S Nelson; Felix Y Feng; David P Labbé; Henry W Long; Eva Corey
Journal:  JCI Insight       Date:  2022-05-23

2.  The Androgen Hormone-Induced Increase in Androgen Receptor Protein Expression Is Caused by the Autoinduction of the Androgen Receptor Translational Activity.

Authors:  Tiziana Siciliano; Ulrich Sommer; Alicia-Marie K Beier; Matthias B Stope; Angelika Borkowetz; Christian Thomas; Holger H H Erb
Journal:  Curr Issues Mol Biol       Date:  2022-01-25       Impact factor: 2.976

3.  Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.

Authors:  Michael D Nyquist; Lisa S Ang; Alexandra Corella; Ilsa M Coleman; Michael P Meers; Anthony J Christiani; Cordell Pierce; Derek H Janssens; Hannah E Meade; Arnab Bose; Lauren Brady; Timothy Howard; Navonil De Sarkar; Sander B Frank; Ruth F Dumpit; James T Dalton; Eva Corey; Stephen R Plymate; Michael C Haffner; Elahe A Mostaghel; Peter S Nelson
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

Review 4.  Understanding and targeting prostate cancer cell heterogeneity and plasticity.

Authors:  Dean G Tang
Journal:  Semin Cancer Biol       Date:  2021-11-26       Impact factor: 17.012
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.